Assessment of patient performance of the HandiHaler® compared with the metered dose inhaler four weeks after instruction

被引:37
作者
Dahl, R
Backer, V
Ollgaard, B
Gerken, F
Kesten, S
机构
[1] Aarhus Univ Hosp, Dept Resp Dis, DK-8000 Aarhus, Denmark
[2] Copenhagen Univ Hosp, Bispebjerg Hosp, Copenhagen, Denmark
[3] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[4] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT 06877 USA
关键词
device; bronchodilator; chronic obstructive pulmonary disease; performance; tiotropium; inhaler technique;
D O I
10.1016/S0954-6111(03)00162-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The HandiHater(R) is a novel breath-actuated dry powder system designed for the delivery of tiotropium 18mug daily in the treatment of COPD. We compared patient ability to use the HandiHaler(R) or metered dose inhaler (MDI) device correctly 4 weeks after receiving brief instructions and device demonstration. A single-blind study was conducted in COPD patients in two centers in Denmark. All patients (n = 151) received one placebo capsule via the HandiHaler(R) daily and ipratropium (20 mug) two actuations via the MDI q.i.d. Mean FEV1 for all patients was 1.25 + 0.54 (46% predicted). Twelve instructions establishing proper device use were evaluated for the MDI and Handihaler. Error scores were analyzed by number of patients with less, equal or more errors when using HandiHaler(R) compared to MDI in the total efficacy population (n = 139) and according to those who had not previously used an MDI for at least 12 months (MDI beginners) (n = 74) and those who had used an MIDI (MDI experienced) (n = 65). Four weeks after device instruction, a higher proportion of patients in the total population (P<0.01) had fewer errors with the HandiHaler(R) (35.3%) compared to the MDI (15.1%). The number of errors was equal in 50% of patients. Similar findings were observed in the subgroup of patients who were MDI beginners (42% vs. 11%, P<0.01) with nonsignificant trends in favor of the HandiHaler(R) 1 in those patients who were MDI experienced (29.7% vs. 18.9%, P = 0.096). Similar results in favor of HandiHaler(R) were noted across different age and sex strata. The proportion of patients correctly using the device on the first of three attempts was 59.7% and 54.7% for the HandiHaler(R) and MDI, respectively (P = 0.399). In summary, use of the HandiHaler(R) can be easily taught with fewer errors compared to the MDI. Furthermore, patient performance using the HandiHaler(R) was superior to that with an MDI despite prior MDI experience and more frequent usage. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1126 / 1133
页数:8
相关论文
共 18 条
[2]   The misconception of using floating patterns as an accurate means of measuring the contents of metered-dose inhaler devices [J].
Cain, WT ;
Oppenheimer, JJ .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2001, 87 (05) :417-419
[3]   A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease [J].
Casaburi, R ;
Mahler, DA ;
Jones, PW ;
Wanner, A ;
San Pedro, G ;
ZuWallack, RL ;
Menjoge, SS ;
Serby, CW ;
Witek, T .
EUROPEAN RESPIRATORY JOURNAL, 2002, 19 (02) :217-224
[4]   Effective delivery of particles with the HandiHaler® dry powder inhalation system over a range of chronic obstructive pulmonary disease severity [J].
Chodosh, S ;
Flanders, JS ;
Kesten, S ;
Serby, CW ;
Hochrainer, D ;
Witek, TJ .
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 2001, 14 (03) :309-315
[5]   Does introduction of new "easy to use" inhalational devices improve medical personnel's knowledge of their proper use? [J].
Chopra, N ;
Oprescu, N ;
Fask, A ;
Oppenheimer, J .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2002, 88 (04) :395-400
[6]  
Cuvelier Antoine, 2002, Respir Care, V47, P159
[7]   A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol [J].
Donohue, JF ;
van Noord, JA ;
Bateman, ED ;
Langley, SJ ;
Lee, A ;
Witek, TJ ;
Kesten, S ;
Towse, L .
CHEST, 2002, 122 (01) :47-55
[8]  
DSOUZA S, 1995, J AEROSOL MED, V8, pS13
[9]  
Fink J B, 2000, Respir Care, V45, P623
[10]   COMBINATION OF SALBUTAMOL INHALATIONAL POWDER AND TABLETS IN ASTHMA [J].
GRIMWOOD, K ;
FERGUSSON, DM ;
DAWSON, KP .
ARCHIVES OF DISEASE IN CHILDHOOD, 1983, 58 (04) :283-285